Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rapid Micro Biosystems (RPID) EBIT (2020 - 2025)

Rapid Micro Biosystems' EBIT history spans 6 years, with the latest figure at -$11.4 million for Q3 2025.

  • For Q3 2025, EBIT rose 5.54% year-over-year to -$11.4 million; the TTM value through Sep 2025 reached -$45.4 million, up 12.47%, while the annual FY2024 figure was -$49.9 million, 11.75% up from the prior year.
  • EBIT for Q3 2025 was -$11.4 million at Rapid Micro Biosystems, up from -$12.1 million in the prior quarter.
  • Across five years, EBIT topped out at -$9.7 million in Q1 2021 and bottomed at -$17.3 million in Q4 2022.
  • The 5-year median for EBIT is -$13.4 million (2024), against an average of -$13.3 million.
  • The largest annual shift saw EBIT crashed 60.0% in 2021 before it increased 29.39% in 2023.
  • A 5-year view of EBIT shows it stood at -$14.6 million in 2021, then dropped by 18.58% to -$17.3 million in 2022, then increased by 29.39% to -$12.2 million in 2023, then rose by 16.07% to -$10.2 million in 2024, then fell by 11.17% to -$11.4 million in 2025.
  • Per Business Quant, the three most recent readings for RPID's EBIT are -$11.4 million (Q3 2025), -$12.1 million (Q2 2025), and -$11.7 million (Q1 2025).